IP Library › Granted Patent US 12,557,999
Granted Patent B2
US 12,557,999 · App. 17/420,202 · Granted Feb 24, 2026

Quantitative measurement of disruptions in the blood brain barrier

Inventors: Craig Ferris (Holden, MA); Ju Qiao (Boston, MA); Praveen Kulkarni (East Walpole, MA); Codi Gharagouzloo (Carlisle, PA)
Assignee: Northeastern University
A61B5/055G01R33/5601G06T2207/10088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,557,999
App. No.
17/420,202
Granted
Feb 24, 2026
Kind
B2
Abstract

Disclosed are methods for determining blood brain barrier disruption in a subject in need thereof. The methods include administering intravascularly a contrast agent to the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in brain parenchyma and/or cerebral spinal fluid within the region of interest.

Claims (35)

1 . A method comprising:

quantifying a disruption of one or more endothelial walls in a region of interest of a subject, the quantifying comprising:

analyzing magnetic resonance imaging (MRI) data of an extravascular space of the region of interest, the MRI data of the extravascular space comprising first MRI data captured at a first time point and second MRI data captured at a second time point, the analyzing the MRI data comprising identifying a first signal intensity in the extravascular space for the first time point and a second signal intensity in the extravascular space for the second time point, the first time point and the second time point being after a paramagnetic or superparamagnetic blood pool contrast agent was introduced into vasculature of the region of interest of the subject, wherein each of the first signal intensity and the second signal intensity is obtained via an MRI device configured with a repetition time (TR) less than 10 ms and a time to echo (TE) less than 300μs;

calculating a change in signal intensity in the region of interest, the change in signal intensity being based on a difference between the first signal intensity and the second signal intensity; and

evaluating the change in signal intensity to measure the disruption of the one or more endothelial walls within the region of interest, wherein the evaluating comprises identifying a disruption in the one or more endothelial walls in response to the change in signal intensity exceeding a predetermined threshold.

2 . The method of claim 1 , wherein each of the first signal intensity and the second signal intensity is obtained by applying a magnetic field to the region of interest; applying a radio frequency pulse sequence with a selected repetition time (TR) and a selected flip angle (FA) to excite protons in the region of interest, wherein the repetition time is less than about 10 ms, and the selected flip angle ranges from 10° to 30°; measuring a response signal during relaxation of the protons at a selected time-to-echo (TE) with magnetic field gradients activated to provide a T 1 -weighted signal from the region of interest, wherein the time-to-echo is an ultra- short time-to-echo, or Zero TE (ZTE), less than 300 μs; and generating an image of the region of interest.

3 . The method of claim 2 , wherein each of the first signal intensity and the second signal intensity are representative of a concentration of the contrast agent in the region of interest.

4 . The method of claim 1 , further comprising setting the time to echo (TE) to less than 30 μs.

5 . The method of claim 1 , further comprising setting the repetition time to a value from 2 to 10 ms.

6 . The method of claim 1 , further comprising setting a flip angle to a value from 10° to 25°.

7 . The method of claim 1 , wherein the first signal intensity is obtained before presence of the contrast agent in a brain parenchyma and the second signal intensity is subsequently obtained after administration of the contrast agent.

8 . The method of claim 1 , wherein each of the first signal intensity and the second signal intensity is obtained on the region of interest at a time when the contrast agent has cleared from a subject's vascular system.

9 . The method of claim 1 , wherein the region of interest is the subject's entire brain.

10 . The method of claim 1 , wherein the contrast agent is ferumoxytol.

11 . The method of claim 10 , wherein ferumoxytol is administered in a dose to produce a starting blood concentration of between 20 and 200 μg/mL Fe.

12 . The method of claim 10 , wherein ferumoxytol is administered in a dose to produce a starting blood concentration of between 40 and 150 μg/mL Fe.

13 . The method of claim 10 , wherein ferumoxytol is administered at a dose of 200 mg to 510 mg elemental iron.

14 . The method of claim 10 , wherein ferumoxytol is administered at a dose of 2 to 14 mg Fe/kg body weight.

15 . The method of claim 10 , wherein ferumoxytol is administered at a dose of 3 to 4 mg Fe/kg body weight.

16 . The method of claim 1 , wherein the subject is a human.

17 . The method of claim 1 , wherein the subject has traumatic brain injury, type 2 diabetes, stroke, or a CNS disorder.

18 . The method of claim 17 , wherein the subject has a CNS disorder; and the CNS disorder is amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, Alzheimer's disease or related dementia, or Parkinson's disease.

19 . The method of claim 1 , wherein the subject has minor cognitive impairment.

20 . A computing system comprising:

one or more processors; and

storage encoded with instructions that, when executed by the one or more processors, cause the one or more processors to perform a method comprising:

quantifying a disruption of one or more endothelial walls in a region of interest of a subject, the quantifying comprising:

analyzing magnetic resonance imaging (MRI) data of an extravascular space of the region of interest, the MRI data of the extravascular space comprising, first MRI data captured at a first time point and second MRI data captured at a second time point, the analyzing the MRI data comprising identifying a first signal intensity in the extravascular space for the first time point and a second signal intensity in the extravascular space for the second time point, the first time point and the second time point being after a paramagnetic or superparamagnetic blood pool contrast agent was introduced into vasculature of the region of interest of the subject, wherein each of the first signal intensity and the second signal intensity is obtained via an MRI device configured with a repetition time (TR) less than 10 ms and a time to echo (TE) less than 300 μs;

calculating a change in signal intensity in the region of interest, the change in signal intensity being based on a difference between the first signal intensity and the second signal intensity; and

evaluating the change in signal intensity to measure the disruption of the one or more endothelial walls within the region of interest, wherein the evaluating comprises identifying a disruption in the one or more endothelial walls in response to the change in signal intensity exceeding a predetermined threshold.

21 . At least one nontransitory computer-readable storage medium having encoded thereon instructions that, when executed by at least one processor, cause the at least one processor to carry out a method comprising:

quantifying a disruption of one or more endothelial walls in a region of interest of a subject, the quantifying comprising:

analyzing magnetic resonance imaging (MRI) data of an extravascular space of the region of interest, the MRI data of the extravascular space comprising first MRI data captured at a first time point and second MRI data captured at a second time point, the analyzing the MRI data comprising identifying a first signal intensity in the extravascular space for the first time point and a second signal intensity in the extravascular space for the second time point, the first time point and the second time point being after a paramagnetic or superparamagnetic blood pool contrast agent was introduced into vasculature of the region of interest of the subject, wherein each of the first signal intensity and the second signal intensity is obtained via an MRI device configured with a repetition time (TR) less than 10 ms and a time to echo (TE) less than 300 μs;

calculating a change in signal intensity in the region of interest, the change in signal intensity being based on a difference between the first signal intensity and the second signal intensity; and

evaluating the change in signal intensity to measure the disruption of the one or more endothelial walls within the region of interest, wherein the evaluating comprises identifying a disruption in the one or more endothelial walls in response to the change in signal intensity exceeding a predetermined threshold.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2022
From: FERRIS, CRAIG; QIAO, JU; KULKARNI, PRAVEEN; GHARAGOUZLOO, CODI
To: NORTHEASTERN UNIVERSITY
Reel/Frame 061685/0454 →
Continuity (2)
Provisional Application 62787819 · Jan 3, 2019
Related Publication 20220087562A1 · Mar 24, 2022
References Cited (123)
US 7788722B1 · Njemanze et al. · 2010 [cited by applicant]
US 7962960B2 · Fudge · 2011 [cited by applicant]
US 8201257B1 · Andres et al. · 2012 [cited by applicant]
US 9274193B2 · Johnson · 2016 [cited by applicant]
US 10338180B2 · McMillan et al. · 2019 [cited by applicant]
US 20010031242A1 · Cremillieux et al. · 2001 [cited by applicant]
US 20020147803A1 · Dodd et al. · 2002 [cited by applicant]
US 20050215881A1 · Van Zijl et al. · 2005 [cited by applicant]
US 20070080685A1 · Bydder et al. · 2007 [cited by applicant]
US 20090246145A1 · Small · 2009 [cited by applicant]
US 20090264733A1 · Corum et al. · 2009 [cited by applicant]
US 20100129292A1 · Jerosch-Herold et al. · 2010 [cited by applicant]
US 20120092010A1 · Corum et al. · 2012 [cited by applicant]
US 20120150048A1 · Kang et al. · 2012 [cited by applicant]
US 20120179028A1 · Caravan et al. · 2012 [cited by applicant]
US 20120268122A1 · Carl · 2012 [cited by applicant]
US 20120289511A1 · Alam · 2012 [cited by applicant]
US 20140084919A1 · Johnson · 2014 [cited by applicant]
US 20150065865A1 · Leigh et al. · 2015 [cited by applicant]
US 20160000945A1 · Nedergaard et al. · 2016 [cited by applicant]
US 20170079581A1 · Walczak · 2017 [cited by examiner]
US 20170102439A1 · McMillan et al. · 2017 [cited by applicant]
US 20190180139A1 · Zach · 2019 [cited by examiner]
US 20190246938A1 · Gharagouzloo et al. · 2019 [cited by applicant]
US 20190247662A1 · Poltroak · 2019 [cited by applicant]
US 20200051246A1 · Carmi · 2020 [cited by examiner]
US 20210298662A1 · Gharagouzloo et al. · 2021 [cited by applicant]
US 20220087562A1 · Ferris et al. · 2022 [cited by applicant]
US 20220110524A1 · Ferris et al. · 2022 [cited by applicant]
CN 102548571A · 2012 [cited by applicant]
RU 2315559C1 · 2008 [cited by applicant]
WO WO2017019182A1 · 2017 [cited by examiner]
WO WO2018094076A1 · 2018 [cited by applicant]
WO WO2020023980A1 · 2020 [cited by applicant]
WO WO2020142696A1 · 2020 [cited by applicant]
WO WO2020154732A1 · 2020 [cited by applicant]
“Feraheme (ferumoxytol) injection label”, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf. Available at least since Feb. 16, 2017 (See https://web.archive.org/web/20170216125428/https://www.… [cited by examiner]
Xu, X. et al. “Dynamic Glucose Enhanced (DGE) MRI for Combined Imaging of Blood-Brain Barrier Break Down and Increased Blood Volume in Brain Cancer.” Magnetic Resonance in Medicine 74:1556-1563 (2015) (Year: 2015). [cited by examiner]
Shah, M. et al. “Evaluating intensity normalization on MRIs of human brain with multiple sclerosis.” Medical Image Analysis 15: 267-282 (2011) (Year: 2011). [cited by examiner]
Perles-Barbacaru, A.T. et al. “A new Magnetic Resonance Imaging method for mapping the cerebral blood volume fraction: the rapid steady-state T1 method.” Journal of Cerebral Blood Flow & Metabolism 27: 618-631 (2007) (Y… [cited by examiner]
Wardlaw, J.M. et al. “Changes in Background Blood-Brain Barrier Integrity Between Lacunar and Cortical Ischemic Stroke Subtypes”. Stroke 39(4):1327-32 (2008) (Year: 2008). [cited by examiner]
Heye, A.K. et al. “Tracer kinetic modelling for DCE-MRI quantification of subtle blood-brain barrier permeability”. NeuroImage 125 446-455 (2016) (Year: 2016). [cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/US2020/012191 mailed Mar. 19, 2020. [cited by applicant]
Morrison et al., “Early Detection of Cerebral Microbleeds Following Mild Traumatic Brain Injury Using QUTE-CE MRI,” Presented Nov. 7, 2018 at the Society for Neuroscience Meeting, San Diego, CA. [cited by applicant]
Bilston et al., “Arterial Pulsation-driven Cerebrospinal Fluid Flow in the Perivascular Space: A Computational Model,” Computer Methods in Biomechanics and Biomedical Engineering, 6(4): 235-241 (2003). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/015223 dated Apr. 6, 2020. [cited by applicant]
Lam et al., “The ultrastructure of spinal cord perivascular spaces: Implications for the circulation of cerebrospinal fluid,” Scientific Reports, 7: 12924 (2017). [cited by applicant]
Lliff et al., “A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β,” Sci Transl Med., 4(147): 147ra111 (2012). [cited by applicant]
Rennels et al., “Evidence for a ‘Paravascular’ Fluid Circulation in the Mammalian Central Nervous System, Provided by the Rapid Distribution of Tracer Protein Throughout the Brain from the Subarachnoid Space,” Brain Res… [cited by applicant]
Taoka et al., “Gadolinium-based Contrast Media, Cerebrospinal Fluid and the Glymphatic System: Possible Mechanisms for the Deposition of Gadolinium in the Brain,” Magnetic Resonance in Medical Sciences, 17(2):111-119 (2… [cited by applicant]
Arai et al., “Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke”, FEBS J. vol. 276, No. 17, pp. 4644-4652, (2009). [cited by applicant]
Assini et al., “Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation”, Behav Brain Res. vol. 204, No. 1, pp. 206-211, (2009). [cited by applicant]
Bane, et al., “Leakage and Water Exchange Characterization of Gadofosveset in the Myocardium”, Magnetic Resonance Imaging, vol. 32, No. 3, pp. 224-235, Apr. 2014. [cited by applicant]
Banerjee et al., “Novel imaging techniques in cerebral small vessel diseases and vascular cognitive impairment”, Biochim. Biophys. Acta—Mot Basis Dis. 1862, pp. 926-938, (2015). [cited by applicant]
Barbier et al., “Methodology of Brain Perfusion Imaging”, Journal of Magnetic Resonance Imaging, vol. 13, pp. 496-520, (2001). [cited by applicant]
Barker et al., “Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank”, Alzheimer Dis Assoc Disord., vol. 16, No. 4, pp.… [cited by applicant]
Bremerich et al., “MR angiography with blood pool contrast agents”, Eur Radial. vol. 17, No. 12, pp. 3017-3024, (2007). [cited by applicant]
Brookheimer et al., “Patterns of brain activation in people at risk for Alzheimer's disease”, N Engl J Med., vol. 343, No. 7, pp. 450-456, (2000). [cited by applicant]
Brunser et al., “Accuracy of diffusion-weighted imaging in the diagnosis of stroke in patients with suspected cerebral infarct”, Stroke, pp. 1169-1171, (2013). [cited by applicant]
Charidimou et al., “Sporadic cerebral amyloid angiopathy revisited: Recent insights into pathophysiology and clinica spectrum”, J Neural Neurosurg Psychiatry., vol. 83, No. 2, pp. 124-137, (2012). [cited by applicant]
Chen et al., “Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies”, J. Biomed Sci., vol. 20, pp. 1-8, (2013). [cited by applicant]
Christen et al., “High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent erumoxytol”, Magn Reson Med., vol. 70, No. 3, pp. 705-710, Sep. 2013. [cited by applicant]
Cunningham et al., “Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles”, Magn Reson Med., vol. 53, No. 5, pp. 999-1005, May 2005. [cited by applicant]
Desai et al., “Evidence of angiogenic vessels in Alzheimer's disease”, J Neural Transm., vol. 116, pp. 587-597, May 2009. [cited by applicant]
Du et al., Qualitative and quantitative ultrashort-TE MRI of cortical bone, NMR Biomed., vol. 26, No. 5, pp. 489-506, May 2013. [cited by applicant]
Filippini et al., “Distinct patterns of brain activity in young carriers of the APOE-?4 allele”, Proc Natl Acad Sci., vol. 106, No. 17, pp. 7209-7214, (2009). [cited by applicant]
Forshult, “Magnetic Resonance Imaging MRI—An Overview”, Karlstad, Sweden: Karlstad University (2007), p. 9. [cited by applicant]
Gharagouzloo et al., “Central Nervous System Diagnostics with QUTE-CE”, Poster presented at Northeastern's University ITNANO Presentation, 1 page (2014). [cited by applicant]
Gharagouzloo et al., “Diagnosing Neuropathey Early with QUTE-CE MRI”, Poster presented at IGERT Illanomedicine 1st Annual Nanomedicine Day, 1 page (2015). [cited by applicant]
Gharagouzloo et al., “ISMRM Abstract”, ISMRM Abstract submitted and poster presented at ISMRM, 1 page (2014). [cited by applicant]
Gharagouzloo et al, “Longitudinal Monitoring of Nanoparticle Accumulation in PC-3 Tumors”, Poster presented at Northeastern University Research, Innovation and Scholarship Expo, 1 page (2015). [cited by applicant]
Gharagouzloo et al, “Positive Contrast Ultrashort TE imaging with Ferumoxytol Contrast Agent”. Poster presented at NCIGT Workshop, 2012, 1 page. [cited by applicant]
Gharagouzloo et al, “Quantitative Imaging of Magnetic Nanoparticles in Mouse Vasculature”, Poster presented at IGERT Nanomedicine 1st Annual Nanomedicine Day, 1 page (2015). [cited by applicant]
Gharagouzloo et al, “Quantitative Positive Contrast MRI with Iron Oxide Nanoparticles”. Poster presented at Northeastern University ITNANO Presentation, 1 page (2013). [cited by applicant]
Gharagouzloo et al, “Quantitative ultra-high resolution MR imaging using magnetic nanoparticles”, Poster presented at NCIGT Workshop, 1 page (2014). [cited by applicant]
Gharagouzloo et al., “Ultra-short TE imaging with SPIONs—Bright prospects for in vivo applications.”, Abstract presented at Northeastern University Research, Innovation and Scholarship Expo, 1 page (2013). [cited by applicant]
Gharagouzloo et al, “Ultrashort TE imaging with SPIONs: bright prospects for in vivo applications”, AACR/SNMMI State-of-the-Art Molecular Imaging in Cancer Biology and Therapy: Abstracts, Molecular Imaging in Cancer, Ab… [cited by applicant]
Gharagouzloo et al, “UTE Angiograpy with ferumoxytol”, Abstract Published at IEEE NEBEC, retrieved from eeexplore.ieee.org/document/6972796; 2 pages (2014). [cited by applicant]
Gharagouzloo et al., “Contrast Enhanced Quantitative UTE (QUTE-CE) MRI for Cerebral Blood Imaging and Cancer Diagnostics”, RISE 2014, Abstract ID# 301, Northeastern University, Apr. 10, 2014. [cited by applicant]
Gharagouzloo et al., “Environment and mobility influence on magnetic nanoparticles with Ferumoxytol”, Poster ; presented at World Molecular Imaging Congress, 1 page (2012). [cited by applicant]
Gharagouzloo et al., “Functional neuroimaging using dynamic radial 3D UTE pulse sequences”, Poster presented at ISMRM, 1 page (2017). [cited by applicant]
Gharagouzloo et al., “Quantitative In Vivo Concentration Determination of Magnetic Nanoplatforms with Ultra-Short TE Magnetic Resonance Imaging UTE”, Poster presented at First International Translational Nanomedicine Co… [cited by applicant]
Gharagouzloo et al., “Quantitative vascular measurements in ApoE-E:-4 knock-in female rats before onset of AD”, International Society for Magnetic Resonance in Medicine, ISMRM, 2030 Addison Street, 7th Floor, Berkeley, … [cited by applicant]
Gharagouzloo et al., “Quantitative vascular neuroimaging of the rat brain using superparamagnetic nanoparticles: New insights on vascular organization and brain function”, Neuroimage.; 163:24-33. doi: 10.1016/j.neuroima… [cited by applicant]
Gharagouzloo, C.A. et al, “Quantitative Contrast-Enhanced MRI with Superparamagnetic Nanoparticles Using Ultrashort Time-to-Echo Pulse Sequences”, Magnetic Resonance Imaging, vol. 74, No. 2, 431-441; EPub; Aug. 28 (onli… [cited by applicant]
Gorelick et al., Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, vol. 42, No. 9, pp. 2672-27… [cited by applicant]
Greenberg et al., “Cerebral microbleeds: a guide to detection and interpretation”, Lancet Neural., 19 pages (2009). [cited by applicant]
Guo et al., “The Vasculome of the Mouse Brain”, PLoS One. vol. 7, 17 pages (2012). [cited by applicant]
Gupta et al., “Impaired Aß clearance: A potential link between atherosclerosis and Alzheimer's disease”, Front Aging Neurosci., 8 pages (2015). [cited by applicant]
Hachinski, V., “Dementia: Paradigm shifting into high gear”, Alzheimers Dement., vol. 15, No. 7, pp. 985-994, Jul. 2019. [cited by applicant]
Iadecola, “The Pathobiology of Vascular Dementia”, Neuron., vol. 80, No. 4, pp. 844-866, (2013). [cited by applicant]
Jack et al., “Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease”, Brain, vol. 132, No. 5, pp. 1355-1365, (2009). [cited by applicant]
Johnson et al., “Hybrid Radial-Cones Trajectory for Accelerated Magnetic Resonance Imaging”, Magn Reson Med., vol. 77, No. 3, pp. 1068-1081, Mar. 2017. [cited by applicant]
Kim et al., In Vivo Quantification of Transvascular Water Exchange During the Acute Phase of Permanent Stroke, Magn Reson Med., vol. 60, No. 4, pp. 813-821, Oct. 2008. [cited by applicant]
Kim, S. et al., “Cerebral Blood Volume MRI with Intravascular Superparamagentic Iron Oxide Nanoparticles”, NMR Biomedicine, vol. 26, No. 8, pp. 949-962, Aug. 2012. [cited by applicant]
Kwon et al., “Simultaneous evaluation of vascular morphology, blood volume and transvascular permeability using SPION-based, dual-contrast MRI: imaging optimization and feasibility test”, NMR In Biomedicine, vol. 28, pp… [cited by applicant]
Kwong et al., “Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation”, Proc Natl Acad Sci USA, vol. 89, No. 12, pp. 5675-5679, (1992). [cited by applicant]
Leaston et al., “Neurovascular imaging with QUTE-CE MRI in APOE4 rats reveals early vascular abnormalities”, PLOS One Aug. 27, 16 pages (2021). [cited by applicant]
Li et al., “Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after :idministration of sildenafil to rats with embolic stroke”, Brain Res., vol. 1132, No. 1, pp. 185-192, (2007). [cited by applicant]
Mandeville, “Iron fMRI measurements of CBV and implications for BOLD signal”, Neuroimage, vol. 62, No. 2, pp. 1000-1008, (2012). [cited by applicant]
Marques et al., “Low-Field MRI: An MR Physics Perspective,” Journal of Magnetic Resonance Imaging, vol. 49, No. 6, pp. 1528-1549, (2019). [cited by applicant]
Murase, “Generalized equation for describing the magnetization in spoiled gradient-echo imaging”, Magnetic Resonance Imaging, vol. 29, No. 5, pp. 723-730, Jun. 2011. [cited by applicant]
Reijmer et al., “Ischemic brain injury in cerebral amyloid angiopathy”, J Cereb Blood Flow Metab, 15 pages (2016). [cited by applicant]
Reiman et al., “Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study”, Lancet Neurol., vol. 11, No… [cited by applicant]
Rohrer et al., “Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths, Investigative Radiology”, vol. 40, No. 11, pp. 715-724, Nov. 2005. [cited by applicant]
Schabel et al., “Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse ,equences”, Phys Med Biol., vol. 53, No. 9, pp. 2345-2373, (2008). [cited by applicant]
Schild, H.H., “MRI made easy( . . . well almost)”, Berlin: Schering AG, p. 96 (1990). [cited by applicant]
Seevinck et al., “Magnetic resonance imaging of brain angiogenesis after stroke”, Angiogenesis, vol. 13, No. 2, pp. 101-111, (2010). [cited by applicant]
Semple et al., “Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species”, Prog Neurobiol., vol. 106, pp. 1-16, Jul. 2013. [cited by applicant]
Shi et al., “Update on cerebral small vessel disease: a dynamic whole-brain disease”, BMJ, vol. 1, No. 3, pp. 83-92, (2016). [cited by applicant]
Stuber et al., “Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON)”, Magn Reson Med., vol. 58, pp. 1072-1077, (2007). [cited by applicant]
Sutphin et al. “Male Pelvic MR Angiography”, Magnetic Resonance Imaging Cln. N. Am. vol. 22, No. 2, May 2014. [cited by applicant]
Tropres et al., Vessel size imaging, Magn Reson Med., vol. 45, pp. 397-408, (2001). [cited by applicant]
Uh et al., “Cerebral blood volume in Alzheimer's disease and correlation with tissue structural integrity”, Neurobiology of Aging, vol. 31, No. 12, pp. 2038-2046, (2010). [cited by applicant]
Walker-Samuel et al., “Reference tissue quantification of DCE-MRI data without a contrast agent calibration”, Phys Med Biol., vol. 52, No., 3, pp. 589-601, Jan. 2007. [cited by applicant]
Wang et al., “Improving detection specificity of iron oxide nanoparticles (ION Ps) using the SWIFT sequence with long T2 suppression”, Magn Reson Imaging, vol. 32, No. 6, pp. 671-678, Jul. 1, 2014. [cited by applicant]
Wardlaw et al., “Mechanisms under1ying sporadic cerebral small vessel disease: insights from neuroimaging”, Lancet Neurol., vol. 12, No. 5, pp. 1-27, (2013). [cited by applicant]
Wardlaw et al., “Neuroimaging standards for research into small vessel disease and its contribution to ageing and 11eurodegeneration”, Lancet Neurol., vol. 12, No. 8, pp. 822-838, (2013). [cited by applicant]
Wey et al., “A review of current imaging methods used in stroke research”, Neurol Res., vol. 35, No. 10, pp. 1092-1102, Dec. 2013. [cited by applicant]
Yankeelov et al., “Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis and Examples”, Curr Med Imaging Rev., vol. 3, No. 2, pp. 91-107, 2009. [cited by applicant]
Zhang et al., “T1-Weighted Ultrashort Echo Time Method for Positive Contrast Imaging of Magnetic Nanoparticles and Cancer Cells Bound With the Targeted Nanoparticles”, J Magn Reson Imaging, vol. 33, No. 1, pp. 194-202, … [cited by applicant]
Zlokovic, “Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders”, Nat. Rev Neurosci., vol. 12, No. 12, pp. 723-738, Dec. 2011. [cited by applicant]
U.S. Appl. No. 17/425,123, Pending. [cited by applicant]